Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

PD-1/PD-L1 checkpoint blockades have achieved significant progress in several kinds of tumours. Pembrolizumab, which targets PD-1, has been approved as a first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with positive PD-L1 expression. However, PD-1/PD-L1 checkpoint block...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xin, Guo, Gaochao, Guan, Hui, Yu, Yang, Lu, Jie, Yu, Jinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380009/
https://www.ncbi.nlm.nih.gov/pubmed/30777100
http://dx.doi.org/10.1186/s13046-019-1085-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380009/
https://www.ncbi.nlm.nih.gov/pubmed/30777100
http://dx.doi.org/10.1186/s13046-019-1085-3

Ejemplares similares